Cargando…

TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine

Migraine is a chronic neurological disorder that affects approximately 12% of the population. The cause of migraine headaches is not yet known, however, when the trigeminal system is activated, neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P (SP) are released, which caus...

Descripción completa

Detalles Bibliográficos
Autores principales: Spekker, Eleonóra, Körtési, Tamás, Vécsei, László
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820749/
https://www.ncbi.nlm.nih.gov/pubmed/36614146
http://dx.doi.org/10.3390/ijms24010700
_version_ 1784865536462553088
author Spekker, Eleonóra
Körtési, Tamás
Vécsei, László
author_facet Spekker, Eleonóra
Körtési, Tamás
Vécsei, László
author_sort Spekker, Eleonóra
collection PubMed
description Migraine is a chronic neurological disorder that affects approximately 12% of the population. The cause of migraine headaches is not yet known, however, when the trigeminal system is activated, neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P (SP) are released, which cause neurogenic inflammation and sensitization. Advances in the understanding of migraine pathophysiology have identified new potential pharmacological targets. In recent years, transient receptor potential (TRP) channels have been the focus of attention in the pathophysiology of various pain disorders, including primary headaches. Genetic and pharmacological data suggest the role of TRP channels in pain sensation and the activation and sensitization of dural afferents. In addition, TRP channels are widely expressed in the trigeminal system and brain regions which are associated with the pathophysiology of migraine and furthermore, co-localize several neuropeptides that are implicated in the development of migraine attacks. Moreover, there are several migraine trigger agents known to activate TRP channels. Based on these, TRP channels have an essential role in migraine pain and associated symptoms, such as hyperalgesia and allodynia. In this review, we discuss the role of the certain TRP channels in migraine pathophysiology and their therapeutic applicability.
format Online
Article
Text
id pubmed-9820749
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98207492023-01-07 TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine Spekker, Eleonóra Körtési, Tamás Vécsei, László Int J Mol Sci Review Migraine is a chronic neurological disorder that affects approximately 12% of the population. The cause of migraine headaches is not yet known, however, when the trigeminal system is activated, neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P (SP) are released, which cause neurogenic inflammation and sensitization. Advances in the understanding of migraine pathophysiology have identified new potential pharmacological targets. In recent years, transient receptor potential (TRP) channels have been the focus of attention in the pathophysiology of various pain disorders, including primary headaches. Genetic and pharmacological data suggest the role of TRP channels in pain sensation and the activation and sensitization of dural afferents. In addition, TRP channels are widely expressed in the trigeminal system and brain regions which are associated with the pathophysiology of migraine and furthermore, co-localize several neuropeptides that are implicated in the development of migraine attacks. Moreover, there are several migraine trigger agents known to activate TRP channels. Based on these, TRP channels have an essential role in migraine pain and associated symptoms, such as hyperalgesia and allodynia. In this review, we discuss the role of the certain TRP channels in migraine pathophysiology and their therapeutic applicability. MDPI 2022-12-31 /pmc/articles/PMC9820749/ /pubmed/36614146 http://dx.doi.org/10.3390/ijms24010700 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Spekker, Eleonóra
Körtési, Tamás
Vécsei, László
TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine
title TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine
title_full TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine
title_fullStr TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine
title_full_unstemmed TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine
title_short TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine
title_sort trp channels: recent development in translational research and potential therapeutic targets in migraine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820749/
https://www.ncbi.nlm.nih.gov/pubmed/36614146
http://dx.doi.org/10.3390/ijms24010700
work_keys_str_mv AT spekkereleonora trpchannelsrecentdevelopmentintranslationalresearchandpotentialtherapeutictargetsinmigraine
AT kortesitamas trpchannelsrecentdevelopmentintranslationalresearchandpotentialtherapeutictargetsinmigraine
AT vecseilaszlo trpchannelsrecentdevelopmentintranslationalresearchandpotentialtherapeutictargetsinmigraine